EUCTR2015-002496-26-ES进行中（未招募）1 期
A phase 3b, randomized, controlled, multicentre study with oral ferric maltol (Feraccru) or intravenous iron (ferric carboxymaltose; FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease - ST10 versus IV iron for IDA in IBD
Iron Therapeutics (UK) Ltd.0 个研究点目标入组 240 人开始时间: 2015年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subjects must be competent to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent form and must sign and date the informed consent prior to any study mandated procedure
- •2. Subjects must be willing and able to comply with study requirements
- •3. Age ? 18 years
- •4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)
- •5. Subjects must be intolerant of oral ferrous products, or considered not suitable for oral ferrous products, and would be considered by the Investigator suitable for intravenous iron treatment
- •6. Subjects must have iron deficiency anemia defined by the following criteria:
- •a. Hb <11.0 g/dL for women OR a Hb <12.0 g/dL for men
- •b. AND Ferritin <100 ng/ml OR Transferrin saturation (TSAT) <20%.
- •7. Female subject of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner. Oral contraceptive medications are allowed in this study. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to
- •participate.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Subject with anaemia due to any cause other than iron deficiency, including, but not limited to,
- •a. Untreated or untreatable severe malabsorption syndrome
- •b. Immunosuppressant use
- •2. Subject who has received prior to screening
- •a. Within 8 weeks intramuscular or intravenous (IV) injection or
- •administration of depot iron preparation
- •b. Within 2 weeks a blood transfusion
- •3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater than 4 or a CDAI score greater than 220
- •4. Subject with known hypersensitivity or allergy to components of ferric maltol or ferric carboxymaltose
- •5. Subjects who have had reactions to previous doses of intravenous iron (i.e. required observation for >2 hours, in-patient admission or medical treatment for infusion reactions)
- •6. Subjects with contraindication for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia
- •7. Subjects with vitamin B12 or folic acid deficiency as determined by the central laboratory results and the clinical opinion of the investigator. Subjects may start vitamin B12 or folate replacement and rescreen after 2 weeks.
- •8. Subjects who are pregnant or breast feeding.
- •9. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anaemia
- •10. Participation in any other interventional clinical study within 30 days prior to screening.
- •11. Subject with cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject or severely limit the lifespan of the subject (i.e. unlikely to complete the full duration of the study)
- •12. Subject with significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results (e.g., Alzheimer?s disease, schizophrenia or other psychosis, active or current alcohol or drug abuse)
- •13. Subject who is an inmate of a psychiatric ward, prison, or other state institution
- •14. Subject who is an Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
研究者
相似试验
进行中（未招募）
1 期
A study of an iron medication for treatment of anaemia (low number of healthy blood cells) in people with inflammatory bowel disease (inflammation of all or part of digestive tract)EUCTR2015-002496-26-BEIron Therapeutics (UK) Ltd.250
进行中（未招募）
1 期
A study of an iron medication for treatment of anaemia (low number of healthy blood cells) in people with inflammatory bowel disease (inflammation of all or part of digestive tract)EUCTR2015-002496-26-HUShield TX (UK) Ltd.242
进行中（未招募）
1 期
A study of an iron medication for treatment of anaemia (low number of healthy blood cells) in people with inflammatory bowel disease (inflammation of all or part of digestive tract)Iron deficiency anaemia with inflammatory bowel diseaseMedDRA version: 20.0 Level: LLT Classification code 10002062 Term: Anaemia iron deficiency System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: PT Classification code 10022972 Term: Iron deficiency anaemia System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-002496-26-DEShield TX (UK) Ltd.242
招募中
3 期
PB016 and Entyvio® in the induction and maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis.CTRI/2023/10/058307Polpharma Biologics S.A.
招募中
1 期
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.ulcerative colitisCTIS2022-502778-18-00Polpharma Biologics S.A.679